The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patients’ quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Group’s ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
Video: Care4Afrique, a pilot cervical cancer screening programme03/02/2023
Dr Farida Selmouni presents the Care4Afrique project and the published report prepared in collaboration with the Lalla Salma Foundation for Cancer Prevention and Treatment (Morocco). Care4Afrique demonstrates that implementation of cervical cancer screening by visual inspection with acetic acid (VIA) followed by immediate treatment of precancerous lesions with thermal ablation in primary health-care services is feasible in resource-constrained settings. View the report and view the video.
New publication: Implementation of a Pilot Cervical Cancer Screening Programme Integrated in Routine Primary Health-Care Services in Benin, Côte d’Ivoire, and Senegal: Report of a Pilot Project (Care4Afrique) in Three African Countries03/02/2023
This publication summarizes the outcomes of the Care4Afrique project aiming to implement cervical cancer screening and treatment in three focus countries in Francophone sub-Saharan Africa – Benin, Côte d’Ivoire, and Senegal – by IARC in close collaboration with the ministries of health of the countries and the Lalla Salma Foundation for Cancer Prevention and Treatment (Morocco). The project highlights solutions to integrate cervical cancer screening and treatment services into routine primary health-care services and overcome some of the common system-level barriers to implementation that are faced in many countries in sub-Saharan Africa. View the report and the IARC Press Release.
kick-off meeting of the project “Enhancing breast cancer knowledge and clinical skills among healthcare providers”31/01/2023 – 01/02/2023
On January 31st and February 1st, scientists from the Early Detection, Prevention and Infections Branch held in Tunis, the kick-off meeting of the project “Enhancing breast cancer knowledge and clinical skills among healthcare providers”. The project will be implemented in the polyclinics of Misrata, Libya. It aims to train 40 master trainers on CBE. Training will be provided by Department Heads of the National Cancer Institute of Misrata. The project is funded by a UICC grant.
CARE4Afrique closing meeting24/01/2023
On January 24th, the closing meeting of the CARE4Afrique project was held virtually with the representatives of Benin, Cameroon, Côte d’Ivoire and Senegal, and the Directors of the Lalla Salma Foundation. Challenges in the project implementation and status in scaling up cervical cancer screening and treatment of precancerous lesions were presented. Two countries already started to provide screen-and-treat services within the country. Key elements were identified for the success of scaling up in Sub-Sahara Africa: dedicated budget, lobbying and community participation, regular training of the providers, approach “screen-and-treat” using VIA and thermal ablation. The launch on February 4th of the CARE4Afrique report on IARC website was announced.
Atlas of Breast Cancer Early Detection23/01/2023
The International Agency for Research on Cancer (IARC) is pleased to announce the launch of a new digital atlas, the Atlas of Breast Cancer Early Detection. The atlas is a step-by-step guide to the procedure of clinical breast examination and its interpretation, diagnostic mammography, diagnostic breast ultrasound, image-guided fine-needle aspiration cytology, and core biopsy of the breast.
View the digital atlas.
|Mandrik O., Roitberg F., Lauby-Secretan B., Parak U., Ramadas K., Varenne B., Sankaranarayanan R., Carvalho A.L. Perspective on oral cancer screening: Time for implementation research and beyond. J Cancer Policy. 2023 Jan 2;35:100381.|
|Singh D., Vignat J., Lorenzoni V., Eslahi M., Ginsburg O., Lauby-Secretan B., Arbyn M., Basu P., Bray F., Vaccarella S. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023 Feb;11(2):e197-e206.|
|Joshi S., Anantharaman D., Muwonge R., Bhatla N., Panicker G., Butt J., Rani Reddy Poli U., Malvi S.G., Esmy P.O., Lucas E., Verma Y., Shah A., Zomawia E., Pimple S., Jayant K., Hingmire S., Chiwate A., Divate U., Vashist S., Mishra G., Jadhav R., Siddiqi M., Sankaran S., Pillai Rameshwari Ammal Kannan T., Kartha P., Shastri S.S., Sauvaget C., Radhakrishna Pillai M., Waterboer T., Muller M., Sehr P., Unger E.R., Sankaranarayanan R., Basu P. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine. 2023 Jan 4;41(1):236-245.|